BRISTOL-MYERS SQUIBB COMPANY

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology MATTERS Rank in Class
 
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 1250 6
 
 
C07D HETEROCYCLIC COMPOUNDS 1046 2
 
 
C07K PEPTIDES 253 10
 
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 140 1
 
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 117 62
 
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 99 22
 
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 84 29
 
 
C07C ACYCLIC OR CARBOCYCLIC COMPOUNDS 74 67
 
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 72 32
 
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 72 127
  • No Technologies to Display

Top Patents (by citation)

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2018/0030,057 SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS CGRP RECEPTOR ANTAGONISTS Sep 21, 17 Feb 01, 18 [C07D]
2018/0016,336 ANTIBODIES AGAINST TIM3 AND USES THEREOF Jul 13, 17 Jan 18, 18 [A61K, C07K]
2018/0002,432 ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF Jul 11, 17 Jan 04, 18 [A61K, G01N, C07K]
2017/0368,172 USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT Jun 03, 17 Dec 28, 17 [A61K, C07K]
2017/0360,759 CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS Jun 20, 17 Dec 21, 17 [C07D, C07C, A61K]
2017/0362,176 CARBAZOLE DERIVATIVES Oct 23, 15 Dec 21, 17 [C07D]
2017/0362,259 PROCESS AND INTERMEDIATES FOR MAKING TUBULYSIN ANALOGS Jun 15, 17 Dec 21, 17 [C07F, C07D]
2017/0354,718 FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN Apr 19, 17 Dec 14, 17 [A61K]
2017/0326,247 ANTIBODY-DRUG CONJUGATES OF TUBULYSIN ANALOGS WITH ENHANCED STABILITY May 05, 17 Nov 16, 17 [A61K, C07K]
2017/0326,249 ANTIBODY-DRUG CONJUGATE OF AN ANTI-GLYPICAN-3 ANTIBODY AND A TUBULYSIN ANALOG, PREPARATION AND USES May 05, 17 Nov 16, 17 [A61K, C07K]

View all publication…

  • No Publications to Display

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9879046 Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions Jul 07, 16 Jan 30, 18 [G01N, A61K, C07K]
9872852 Compounds useful as immunomodulators Sep 02, 14 Jan 23, 18 [C07D, C07C, A61K, C07K]
9873679 Pyrrolidine GPR40 modulators May 06, 15 Jan 23, 18 [C07D, A61K]
9868743 Macrocyclic molecules as HCV entry inhibitors Feb 04, 14 Jan 16, 18 [A01N, C07D, A61P, A61K]
9861680 Immunomodulators Dec 14, 15 Jan 09, 18 [A61K, C07K]
9862715 Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors Dec 07, 15 Jan 09, 18 [C07D]
9862730 Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation Apr 24, 13 Jan 09, 18 [C07D, A61K]
9862758 Inhibitors of type 2 vascular endothelial growth factor receptors Mar 15, 16 Jan 09, 18 [C12N, C07H, A61K, C07K]
9856244 Dihydropyridinone MGAT2 inhibitors Jun 08, 17 Jan 02, 18 [C07D, A61K]
9856292 Immunomodulators Nov 11, 15 Jan 02, 18 [A61K, C07K]

View all Patent…

  • No Patents to Display

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2017/0260,232 TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE ABAN May 23, 17 Sep 14, 17 [A61K, C07K]
2017/0057,961 MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES ABAN Jan 30, 15 Mar 02, 17 [C07D]
2016/0318,904 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS ABAN Jul 08, 16 Nov 03, 16 [C07D]
2016/0304,607 COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTIBODY ABAN Apr 15, 16 Oct 20, 16 [C07K]
2016/0274,108 DIAGNOSTIC METHODS FOR PAR4 ANTAGONIST THERAPY ABAN Oct 24, 14 Sep 22, 16 [A61K, G01N]
2016/0222,060 Immunomodulators ABAN Feb 01, 16 Aug 04, 16 [C07K]
2016/0152,686 FIBRONECTIN BASED SCAFFOLD DOMAINS LINKED TO SERUM ALBUMIN OR MOIETY BINDING THERETO ABAN Mar 12, 14 Jun 02, 16 [C07K]
2016/0153,990 METHODS FOR IDENTIFYING PATIENTS AT RISK FOR COSTIMULATION BLOCKADE RESISTANT REJECTION ABAN Mar 27, 14 Jun 02, 16 [G01N]
2016/0038,502 HIV TREATMENT FORMULATION OF ATAZANAVIR AND COBICISTAT ABAN Oct 06, 14 Feb 11, 16 [A61K]
2016/0024,203 METHODS OF PRODUCING ANTIBODIES IN YEAST ABAN Mar 14, 14 Jan 28, 16 [C07K]
2016/0024,204 METHODS FOR PRODUCING ANTIBODIES ABAN Mar 14, 14 Jan 28, 16 [C07K]
2015/0336,975 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION ABAN Aug 03, 15 Nov 26, 15 [C07D]
2015/0299,136 LXR MODULATORS ABAN May 04, 15 Oct 22, 15 [C07D]
2015/0299,804 BIOMARKERS FOR PREDICTING CLINICAL RESPONSE OF CANCER PATIENTS TO TREATMENT WITH IMMUNOTHERAPEUTIC AGENT ABAN Nov 14, 13 Oct 22, 15 [C12Q, G06F, C07K]
2015/0290,316 COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT CANCER ABAN Oct 02, 13 Oct 15, 15 [A61K, C07K]
2015/0266,856 RORGamma Modulators ABAN Oct 17, 13 Sep 24, 15 [C07D]
2015/0252,028 HEPATITIS C VIRUS INHIBITORS ABAN Oct 24, 12 Sep 10, 15 [C07D, A61K]
2015/0252,097 TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KINASES RECEPTORS, INCLUDING IGF-IR ABAN Mar 16, 15 Sep 10, 15 [A61K, C07K]
2015/0225,790 METHODS FOR IDENTIFYING SUBJECTS WITH AN INCREASED LIKELIHOOD OF RESPONDING TO CCR1 ANTAGONIST ABAN Apr 18, 13 Aug 13, 15 [C12Q]
2015/0210,691 LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS ABAN Apr 08, 15 Jul 30, 15 [C07D, A61K, A61J, B65D]

View all Patent…

  • No Patents to Display

Top Inventors for This Owner

We are sorry but your current selection exceeds the maximum number of watches () for this membership level. Upgrade to our Level for up to watches!

Owner Watch
BRISTOL-MYERS SQUIBB COMPANY
CANCEL
UPGRADE MEMBERSHIP CANCEL

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to comparisons!

UPGRADE MEMBERSHIP CANCEL

We are sorry but your current selection exceeds the maximum number of portfolios () for this membership level. Upgrade to our Level for up to portfolios!

UPGRADE MEMBERSHIP CANCEL

We are sorry but your current selection exceeds the maximum number of patents allowed in portfolios () for this membership level. Upgrade to our Level for up to patents!

UPGRADE MEMBERSHIP CANCEL